Skip to main content
SpringerLink
Log in

Pharmacologic modulation of TNF production by endotoxin stimulated macrophages:In vitro andin vivo effects of auranofin and other chrysotherapeutic compounds

  • Inflammation and Immunomodulation
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

The gold compounds, auranofin, sodium aurothiomalate, and triethyl gold phosphine have been demonstrated to inhibit various effector functions associated with monocyte-macrophage populations. Incubation of human peripheral blood monocytes and murine peritoneal macrophages with auranofin or triethyl gold phosphine inhibited TNF production in lipopolysaccharide [LPS] stimulated murine peritoneal macrophages. The inhibitory effect of auranofin and triethyl gold phosphine on LPS stimulated monokine production was reversible when these compounds were incubated with macrophage cultures at concentrations between 0.1–0.5 μg/ml. These compounds also inhibited both TNF and IL-1 production by human peripheral blood monocytes. Sodium aurothiomalate at these concentrations had no inhibitory effect on TNF or IL-1 production. Auranofin and triethyl gold phosphine also inhibited TNF production in vivo when compounds were administered orally or intraperitoneally 2 hours prior to a lethal dose of endotoxin. Serum TNF levels from Balb/c mice were significantly reduced when animals were predosed with 1–25 mg/kg of auranofin. The data suggest that the inhibition of TNF production by activated macrophages may contribute to the therapeutic role of gold compounds in the management of chronic inflammatory disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. M. Chaffman, R. N. Brogden, R. C. Heel, T. M. Speight and G. S. Avery,Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs27, 378–424 (1984).

    PubMed  Google Scholar 

  2. A. J. Lewis, and D. T. Walz,Immunopharmacology of gold. Prog. in Medicinal Chem.19, 1–58 (1982).

    Google Scholar 

  3. N. Hanna, M. J. Di Martino, D. E. Griswold and G. Poste,Immunology of Auranofin — An overview. Proc. of Smith Kline Internatl. Sypos. 60–70 (1982).

  4. D. T. Walz, M. J. Di Martino, B. Sutton and A. Misher,SK&F 36914 — An agent for oral chrysotherapy. J. Pharm. Exp. Ther.181, 292–297 (1972).

    Google Scholar 

  5. D. T. Walz, M. J. Di Martino, L. W. Charkrin, B. M. Sutton and A. Misher,Antiarthritic properties and unique pharmacologic profile of a potential chrysotherapeutic agent: SK&F D-39162. J. Pharm. Exp. Ther.191, 142–152 (1976).

    Google Scholar 

  6. L. M. DeYoung, D. A. Spires, J. Kheifets, and T. G. Terrell,Biology and pharmacology of recombinant human interleukin-β induced rat ear inflammation. Agents and Actions21, 325–327 (1987).

    Article  PubMed  Google Scholar 

  7. D. T. Walz, M. J. DiMartino and D. E. Griswold,Comparative pharmacology and biological effects of different gold compounds. J. Rheumatol.9 (Suppl. 8), 54–60 (1982).

    Google Scholar 

  8. R. M. Snyder, C. K. Mirabelli and S. T. Crooke,Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem. Pharmacol.35, 923–932 (1986).

    Article  PubMed  Google Scholar 

  9. R. M. Snyder, C. K. Mirabelli and S. T. Crooke,Cellular interactions of auranofin and a related gold complex with RAW 264.7 macrophages. Biochem. Pharmacol.36, 647–654 (1987).

    Article  PubMed  Google Scholar 

  10. E. R. Unanue and P. M. Allen,The basis for the immunoregulatory role of macrophages and other accessory cells. Science236, 551–557 (1987).

    PubMed  Google Scholar 

  11. C. F. Nathan,Secretory products of macrophages. J. Clin. Invest.79, 319–326 (1987).

    PubMed  Google Scholar 

  12. D. O. Adams and T. A. Hamilton,The cell biology of macrophage activation. Ann. Rev. Immunol.2, 283–318 (1984).

    Article  Google Scholar 

  13. M. A. Scheinberg, L. Santos and A. Finkelstein,The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J. Rheumatol.9, (3), 366–369 (1982).

    PubMed  Google Scholar 

  14. M. L. Barrett and G. P. Lewis,Unique properties of auranofin as a potential anti-rheumatic drug. Agents and Actions19, 109–115 (1986).

    PubMed  Google Scholar 

  15. J. C. Lee, M. J. Di Martino, B. J. Votta and N. Hanna,Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant rats. J. Immunol.139, 3268–3274 (1987).

    PubMed  Google Scholar 

  16. D. E. Griswold, J. C. Lee, G. Poste and N. Hanna,Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. J. Rheumatol.12, 490–497 (1985).

    PubMed  Google Scholar 

  17. D. A. Flick and G. E. Gifford,Comparison of in vitro cytotoxic assays for tumor necrosis factor. J. Immunol. Methods68, 167–175 (1984).

    Article  PubMed  Google Scholar 

  18. N. L. Gottlieb,Pharmacology of Auranofin: Overview and Update. Scans. J. Rheumatol.63, 19–28 (1986).

    Google Scholar 

  19. R. J. Coughlan, M. B. Richter and G. S., Panayi, Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin. Clin. Rheumatol.3, Supp. 25–32 (1984).

  20. K. J. Tracey, Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry and A. Cerami,Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature330, 662–664 (1987).

    PubMed  Google Scholar 

  21. S. W. Lee, A.-P. Tsou, H. Chan, J. Thomas, K. Petrie, E. M. Eugui and A. C. Allison,Glucocorticoids selectively inhibit the transcription of the interleukin 1-β gene and decrease the stability of interleukin 1-β mRNA. Proc. Nat. Acad. Sci. USA85, 1204–1208 (1988).

    PubMed  Google Scholar 

  22. B. Beutler and A. Cerami,Cachectin: More than a tumor necrosis factor. New England J. Med.316, 379–385 (1987).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Eli Lilly and Company, 46285, Indianapolis, IN, USA

    G. F. Evans & S. H. Zuckerman

Authors
  1. G. F. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. H. Zuckerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Author for correspondence.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Evans, G.F., Zuckerman, S.H. Pharmacologic modulation of TNF production by endotoxin stimulated macrophages:In vitro andin vivo effects of auranofin and other chrysotherapeutic compounds. Agents and Actions 26, 329–334 (1989). https://doi.org/10.1007/BF01967297

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01967297

Keywords

Search

Navigation